Lameditech signs a domestic distribution agreement with Iretech Korea for similar ECM products.

Lameditech Co., Ltd., a laser healthcare specialist, announced on the 17th that it has signed a domestic distribution and strategic cooperation agreement for acellular allograft dermis (ECM, Extra Cellular Matrix) products with Iretech Korea Co., Ltd., a regenerative medical biomaterial specialist.

This collaboration is seen as a strategic move for Lameditech to expand its business into the regenerative medicine field, as homogeneous ECM-based biomaterials are emerging as a key trend in the recent skin regeneration treatment market.

In the global and domestic skin regeneration and aesthetic medicine markets, demand is growing for biomaterial-based treatments that promote tissue regeneration, moving beyond simple volume-replenishing procedures. Allogeneic ECM is a material that removes cellular components from human tissue, minimizing immune responses while preserving collagen structure and biosignals.

Through this agreement, Lameditech secures domestic sales rights for the ECM product and plans to actively establish a new growth business focused on skin regeneration and wound treatment. In particular, with growing demand from medical professionals for complex treatment solutions combining laser and energy-based medical devices with biomaterials, this collaboration is considered to be in line with market trends.

The company is currently developing an integrated skin regeneration solution that combines its currently under-development laser DDS (Drug Delivery System) technology with a homologous ECM to enhance skin barrier penetration efficiency and maximize the efficacy of regenerative materials. Laser DDS utilizes specific wavelengths to minimize tissue damage while enhancing the delivery of effective ingredients. Its integration with ECM is expected to enable a differentiated treatment approach.

Through this collaboration, Lameditech plans to expand its existing laser medical device-centered business structure to focus on regenerative medical solutions and secure mid- to long-term growth momentum.


  • See more related articles